{
    "id": "yago_17905_3",
    "rank": 79,
    "data": {
        "url": "https://markets.businessinsider.com/news/stocks/maxim-group-sticks-to-its-buy-rating-for-acurx-pharmaceuticals-acxp-1033395001",
        "read_more_link": "",
        "language": "en",
        "title": "Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)",
        "top_image": "https://markets.businessinsider.com/favicon-32x32.png",
        "meta_img": "https://markets.businessinsider.com/favicon-32x32.png",
        "images": [
            "https://q.quora.com/_/ad/86a17ac98ee64d3f95ecc7a88fa965b0/pixel?tag=ViewContent&noscript=1",
            "https://markets.businessinsider.com/public/assets/MI/logos/MI-logo-dark-new.svg",
            "https://markets.businessinsider.com/public/assets/MI/logos/MI-logo-dark-new.svg",
            "https://markets.businessinsider.com/public/assets/BI/US/icons/facebook.svg",
            "https://markets.businessinsider.com/public/assets/BI/US/icons/facebook.svg",
            "https://markets.businessinsider.com/public/assets/BI/US/icons/twitter.svg",
            "https://markets.businessinsider.com/public/assets/BI/US/icons/twitter.svg",
            "https://markets.businessinsider.com/public/assets/logos/stacked-black.svg",
            "https://markets.businessinsider.com/public/assets/logos/stacked-black.svg",
            "https://markets.businessinsider.com/public/assets/shared/privacy-options.svg",
            "https://markets.businessinsider.com/public/assets/shared/privacy-options.svg",
            "https://markets.businessinsider.com/public/assets/INSIDER/US/logos/Insider-logo-dark-opt.svg",
            "https://markets.businessinsider.com/public/assets/INSIDER/US/logos/Insider-logo-dark-opt.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Tipranks"
        ],
        "publish_date": "2024-05-16T17:05:39+00:00",
        "summary": "",
        "meta_description": "In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Acurx Pharmaceuticals (ACXP &#8211; Research Report),...",
        "meta_lang": "en",
        "meta_favicon": "/apple-touch-icon.png",
        "meta_site_name": "markets.businessinsider.com",
        "canonical_link": "https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-buy-rating-for-acurx-pharmaceuticals-acxp?utm_source=markets.businessinsider.com&utm_medium=referral",
        "text": "In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report), with a price target of $10.00. The company’s shares opened today at $2.27.\n\nMcCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inmune Bio, and Indaptus Therapeutics. According to TipRanks, McCarthy has an average return of -15.0% and a 30.41% success rate on recommended stocks.\n\nThe word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acurx Pharmaceuticals with a $11.00 average price target, implying a 384.58% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.\n\nBased on Acurx Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.11 million. In comparison, last year the company had a GAAP net loss of $3.26 million\n\nTipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.\n\nAcurx Pharmaceuticals (ACXP) Company Description:\n\nAcurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration."
    }
}